Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CRSP 
Crispr Therapeutics AG (CRSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: CRSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $81.33
1 Year Target Price $81.33
| 12 | Strong Buy |
| 5 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.52% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.25B USD | Price to earnings Ratio - | 1Y Target Price 81.33 |
Price to earnings Ratio - | 1Y Target Price 81.33 | ||
Volume (30-day avg) 28 | Beta 1.73 | 52 Weeks Range 30.04 - 78.48 | Updated Date 12/27/2025 |
52 Weeks Range 30.04 - 78.48 | Updated Date 12/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -14854.78% |
Management Effectiveness
Return on Assets (TTM) -13.28% | Return on Equity (TTM) -25.33% |
Valuation
Trailing PE - | Forward PE 23.36 | Enterprise Value 3544450833 | Price to Sales(TTM) 136.92 |
Enterprise Value 3544450833 | Price to Sales(TTM) 136.92 | ||
Enterprise Value to Revenue 101.27 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 95300233 | Shares Floating 94841839 |
Shares Outstanding 95300233 | Shares Floating 94841839 | ||
Percent Insiders 1.58 | Percent Institutions 77.94 |
Upturn AI SWOT
Crispr Therapeutics AG
Company Overview
History and Background
CRISPR Therapeutics AG was founded in 2013 by a team of leading scientists in the field of CRISPR-Cas9 gene editing. The company aims to develop transformative gene-based medicines for serious diseases. Key milestones include the development of its gene editing platform, strategic partnerships, and clinical trial progress. It has evolved into a clinical-stage biopharmaceutical company focused on translating CRISPR-Cas9 technology into innovative therapies.
Core Business Areas
- Gene Editing Platform Development: CRISPR Therapeutics leverages its proprietary CRISPR-Cas9 gene editing technology to develop novel therapies. This involves identifying target genes, designing guide RNAs, and delivering the editing machinery into cells. The platform is adaptable for various therapeutic applications.
- Therapeutic Pipeline Development: The company focuses on developing a pipeline of gene-edited therapies for a range of serious diseases, particularly in areas with high unmet medical need. This includes hematologic diseases, solid tumors, and rare genetic disorders.
Leadership and Structure
The leadership team is comprised of experienced professionals in biotechnology, drug development, and business management. The organizational structure is typical of a clinical-stage biopharmaceutical company, with dedicated departments for research and development, clinical operations, manufacturing, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Exa-cel (Casgevy): A gene-edited therapy for sickle cell disease and transfusion-dependent beta-thalassemia. It is developed in collaboration with Vertex Pharmaceuticals. Market share data is nascent as it is a newly approved therapy. Competitors include other gene therapy developers and existing treatments for these conditions.
- Voxelotor (Oxbryta): While developed by Global Blood Therapeutics (acquired by Pfizer), CRISPR Therapeutics has a strategic interest in related genetic disease treatments. It is a treatment for sickle cell disease. Competitors include other sickle cell disease treatments.
- Pipeline Candidates (e.g., CTX001, CTX110, CTX120, CTX200): A portfolio of gene-edited therapies in various stages of clinical development for diseases such as sickle cell disease, beta-thalassemia, certain cancers (e.g., B-cell malignancies), and other rare genetic disorders. Market share is not applicable as these are in development. Competitors are other biotechs and pharma companies developing similar gene therapies or alternative treatments.
Market Dynamics
Industry Overview
The gene editing and gene therapy market is a rapidly evolving and highly innovative sector within the biopharmaceutical industry. It is characterized by significant scientific advancements, substantial investment, and the potential to offer one-time cures for previously intractable diseases. The regulatory landscape is also developing, with increasing clarity on approval pathways.
Positioning
CRISPR Therapeutics is positioned as a leader in the development of CRISPR-Cas9 gene editing therapies. Its key competitive advantages include its proprietary technology platform, strong scientific expertise, strategic partnerships with established pharmaceutical companies, and a robust clinical pipeline. The company's focus on translating cutting-edge science into potentially curative treatments is a core differentiator.
Total Addressable Market (TAM)
The Total Addressable Market for gene therapies is substantial and growing, encompassing rare genetic diseases, hematologic disorders, oncology, and other complex conditions. For exa-cel (Casgevy) alone, the TAM for sickle cell disease and beta-thalassemia is estimated to be in the billions of dollars annually. CRISPR Therapeutics is well-positioned to capture a significant portion of this TAM through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary CRISPR-Cas9 gene editing technology
- Strong scientific leadership and research capabilities
- Robust clinical pipeline with multiple promising candidates
- Strategic partnerships with major pharmaceutical companies (e.g., Vertex Pharmaceuticals)
- First-mover advantage in certain gene editing applications
- Potential for transformative, one-time curative therapies
Weaknesses
- High cost of development and manufacturing for gene therapies
- Long development timelines and clinical trial risks
- Reliance on key strategic partnerships for commercialization and manufacturing
- Potential for off-target edits and immunogenicity concerns
- Limited commercial track record as a relatively young company
Opportunities
- Expanding the pipeline to address a broader range of diseases
- Leveraging gene editing for new therapeutic modalities
- Developing next-generation gene editing technologies
- Exploring partnerships for different therapeutic areas or geographies
- Increasing regulatory clarity and faster approval pathways for gene therapies
- Growth in the global market for advanced therapies
Threats
- Competition from other gene editing and gene therapy companies
- Unforeseen safety or efficacy issues in clinical trials
- Challenges in scaling up manufacturing and ensuring consistent product quality
- Reimbursement hurdles and payer acceptance of high-cost therapies
- Intellectual property disputes and patent challenges
- Evolving scientific understanding and potential for superior technologies to emerge
Competitors and Market Share
Key Competitors
- Vertex Pharmaceuticals (VRTX)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
- BioNTech SE (BNTX) (for certain oncology applications)
- Moderna, Inc. (MRNA) (for certain oncology applications)
Competitive Landscape
CRISPR Therapeutics faces intense competition from other gene editing and gene therapy companies. While it has a strong technological foundation and promising pipeline, it must navigate a complex regulatory environment and demonstrate long-term safety and efficacy. Its strategic partnerships, particularly with Vertex, provide a significant advantage in commercialization and market access.
Growth Trajectory and Initiatives
Historical Growth: CRISPR Therapeutics has experienced significant growth in its operational scale and pipeline advancement since its inception. This growth has been driven by scientific innovation, successful fundraising, and strategic collaborations.
Future Projections: Future growth is projected to be driven by the successful clinical development and commercialization of its gene-edited therapies, particularly exa-cel (Casgevy), and the expansion of its pipeline. Analyst estimates anticipate substantial revenue growth in the coming years.
Recent Initiatives: Key recent initiatives include the regulatory approval and launch of exa-cel (Casgevy), advancement of its oncology pipeline candidates (e.g., CTX110, CTX120) into clinical trials, and ongoing research into new gene editing applications.
Summary
CRISPR Therapeutics is a pioneering gene editing company with a strong technological foundation and a promising clinical pipeline, highlighted by the approval of exa-cel. Its main strengths lie in its innovative platform and scientific expertise. However, it faces challenges related to high development costs, long timelines, and intense competition. Continued focus on clinical success, manufacturing scalability, and market access will be crucial for its future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company financial reports (10-K, 10-Q)
- Investor presentations
- Industry analysis reports
- Biopharmaceutical news outlets
- Reputable financial data providers
Disclaimers:
This analysis is based on publicly available information and may not be exhaustive. It is not intended as investment advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crispr Therapeutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-10-19 | CEO & Chairman Dr. Samarth Kulkarni Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://www.crisprtx.com |
Full time employees 393 | Website https://www.crisprtx.com | ||
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.